Concurrent Neoadjuvant Chemoradiotherapy for Siewert II and III Adenocarcinoma at Gastroesophageal Junction

Qun Zhao, MD, Yong Li, MD, Jun Wang, MD, Jun Zhang, MM, Xueying Qiao, MM, Bibo Tan, MD, Yuan Tian, MM, Gaofeng Shi, MD, Qian Xu, MM, Ruxun Li, MM, Yueping Liu, MM and Peigang Yang, MM

Abstract: Objective: This study was conducted to investigate the efficacy and safety of using a concurrent neoadjuvant chemoradiotherapy (a XELOX regimen) to treat adenocarcinoma of the gastroesophageal junction. Methods: Seventy-six patients having resectable adenocarcinoma at the gastroesophageal junction (T3/4, N+, M0) were recruited to participate and randomly assigned to either a chemoradiotherapy group or a surgery group. Patients in the chemoradiotherapy group were orally given capcitabine (1,000 mg/m², twice daily for 14 days, days 1–14) and intravenous oxaliplatin (130 mg/m² on day 1) for 2 cycles. Radiotherapy was performed with a total of 45 Gy administered in 25 sessions for 5 weeks. Patients in the surgery group received only surgical intervention. Results: In the concurrent chemoradiotherapy group, the overall response rate was 55.6% (20/36), tumor control rate was 100% and a pathological complete response was achieved in 16.7% (6/36). The entire chemoradiotherapy group had R0 resections as did 80% of the surgery group (32/40) (P < 0.05). In the concurrent chemoradiotherapy group, 6 patients developed grade 3 side effects. Treatment was either discontinued or the dose adjusted. Major hematological side effects included nausea, vomiting and appetite loss. Chemoradiotherapy-related death was not observed. Conclusions: Concurrent neoadjuvant chemoradiotherapy administration increased the rate of R0 resection and demonstrated favorable safety in patients with Siewert II or III adenocarcinoma at the gastroesophageal junction. These results support the use of neoadjuvant chemoradiotherapy in the treatment of adenocarcinoma of the gastroesophageal junction.

Key Indexing Terms: Neoadjuvant chemoradiotherapy; Gastroesophageal junction; Treatment. [Am J Med Sci 2015;349(6):472–476.]

Therapeutic modalities for esophageal cancer have progressed from surgery alone to surgery combined with radiotherapy, chemotherapy and/or targeted therapy. Compared with surgery alone, concurrent neoadjuvant chemoradiotherapy may significantly increase the radical resection rate and improve the prognosis of esophageal1,2 and rectal cancer patients.3 However, debate still exists regarding gastroesophageal junction adenocarcinoma therapy selection.4,5 Some clinical studies6–7 show that preoperative concurrent neoadjuvant chemoradiotherapy may result in increased pathological complete response and R0 resection rates with tolerable side effects, such as lower negative pathological nodes.6 However, most of these studies were conducted in the United States and Europe.8 Researchers in Western countries found that obesity and frequent reflux in combination were associated with considerably higher risk for gastroesophageal junction adenocarcinoma than either single factor alone. Comparing with Eastern countries, shifts in dietary practices in recent decades toward increased fat intake and consumption of meats in Western countries may have contributed in part to the rising incidence of gastroesophageal junction adenocarcinoma.9 Therefore, few studies have investigated the efficacy of neoadjuvant chemoradiotherapy in Asians with adenocarcinoma gastroesophageal junction adenocarcinomas. In this study, patients having adenocarcinoma located at the gastroesophageal junction were recruited from Hebei Province, China, and received concurrent neoadjuvant chemoradiotherapy. The therapeutic efficacy and safety of this regimen was evaluated.

MATERIALS AND METHODS

General Information

A total of 76 patients with resectable adenocarcinoma at the gastroesophageal junction (T3/4, N+, M0) were recruited at the Fourth Hospital of Hebei Medical University, China, between August 2012 and August 2013. Each was randomly assigned to one of 2 groups: a concurrent chemoradiotherapy group (n = 36) or a surgery group (n = 40). Patients in the concurrent chemoradiotherapy group (32 men and 4 women, median age: 61 years, range: 46–73 years) received concurrent chemoradiotherapy and subsequently surgery. Patients in the surgery group (32 men and 8 women, median age: 57 years, range: 42–72 years) were treated with surgery alone. The general clinical characteristics of patients in the 2 groups are shown in Table 1. This study was approved by the Ethics Committee of the Fourth Hospital of Hebei Medical University and was registered at ClinicalTrials.gov (NCT01962246).

Patient-incclusion criteria for this study were as follows: (1) confirmation, by gastroscopy and CT, of Siewert II or III adenocarcinoma of the gastroesophageal junction with a presurgery tumor long diameter of ≤8 cm; (2) presurgery classification as progressive gastric cancer (T3/4, N+, M0) using the American Joint Committee on Cancer (American Joint Committee on Cancer, AJCC) 2010 patient classification with no evidence of metastasis to the liver, lung, brain, bone or other organs; (3) no prior antimtor therapy; (4) no contraindications for chemotherapy or surgery; (5) a Karnofsky Performance Status (KPS) score of >60 and an Eastern Cooperative Oncology Group (ECOG) score of 0 to 2 and (6) informed consent obtained before enrollment.
TABLE 1. General clinical characteristics of the subjects

|                          | Concurrent chemotherapy (n = 36) | Surgery alone (n = 40) |
|--------------------------|----------------------------------|-----------------------|
| Age, yr                  |                                  |                       |
| Median                   | 61                               | 57                    |
| Range                    | 46–73                            | 42–72                 |
| Gender, n (%)            |                                  |                       |
| M                        | 32 (88.9)                        | 32 (80)               |
| F                        | 4 (11.1)                         | 8 (20)                |
| Degree of tumor differentiation, n (%) |                  |                       |
| Moderately differentiated | 14 (38.9)                        | 18 (45)               |
| Poorly differentiated    | 16 (44.4)                        | 18 (45)               |
| Mucinous adenocarcinoma  | 6 (16.7)                         | 4 (10)                |
| Vertical axis diameter of the tumor, cm |                  |                       |
| Median                   | 4                                | 4                     |
| Range                    | 3–6                              | 3–7                   |
| HER2 expression          |                                  |                       |
| 0                        | 10 (27.8)                        | 16 (40)               |
| 1+                       | 14 (38.9)                        | 16 (40)               |
| 2+ (FISH: negative)      | 10 (27.8)                        | 6 (15)                |
| 3+ (or FISH: positive)   | 2 (5.5)                          | 2 (5)                 |
| Clinical T stage, n (%)  |                                  |                       |
| cT3                      | 14 (38.9)                        | 16 (40)               |
| cT4                      | 22 (61.1)                        | 24 (60)               |
| Clinical N stage, n (%)  |                                  |                       |
| cN0                      | 12 (33.3)                        | 16 (40)               |
| cN1                      | 18 (50)                          | 18 (45)               |
| cN2                      | 6 (16.7)                         | 6 (15)                |
| ECOG score, n (%)        |                                  |                       |
| 0                        | 4 (11.1)                         | 8 (20)                |
| 1                        | 28 (77.8)                        | 24 (60)               |
| 2                        | 4 (11.1)                         | 8 (20)                |

**Chemotherapy Regimen**

The following XELOX regimen was used. Capecitabine was administered 1,000 mg/m² twice daily for 14 days (days 1–14), and oxaliplatin was given intravenously 130 mg/m² on day 1 for 2 cycles. Two chemotherapy cycles were administered before surgery and 6 cycles after.

**Radiotherapy Regimen**

Concurrent CT-based 3-dimensional conformal radiotherapy was delivered by a linear accelerator as multiple shaped beams of 6 to 20 MV X-rays in 5 daily fractions of 1.8 Gy per week for 5 weeks (total dose: 45 Gy). The biologically effective dose, calculated using the linear-quadratic formalism and an α/β ratio of 10 for early responding-tissues (tumor), was 51.1 Gy. According to tolerance of different patients, the chosen dosage ranged from 50 to 52 Gy.

Radiation targets included the entire adenocarcinoma of gastroesophageal junction, any perigastric extension and lymph nodes (gastric, celiac, porta hepatitis, gastroduodenal, splenic-suprapancreatic and retropancreatic-duodenal), with adequate margins. The distal margins of the esophagus (3–5 cm) were included when the tumor involved the gastroesophageal junction.

**Therapeutic Efficacy Determinations**

Therapeutic efficacy was determined according to the Response Evaluation Criteria In Solid Tumors (RECIST Version 1.1) and included the following categories: complete response (CR), partial response (PR), stable disease (SD) and progressive disease. The response rate (RR) was calculated as the sum of CR and PR. The tumor control rate was calculated as the sum of CR, PR and SD. Tumor node metastasis (TNM) staging was performed according to the criteria developed by American Joint Committee on Cancer (7th edition).

**Surgery**

Surgical treatment consisted of either (1) proximal subtotal gastrectomy or (2) total gastrectomy and a subsequent extended lymph node dissection (D2 resection).

**Pathological Analysis**

Pathological examinations included detecting tumor; invasion depth; number of metastatic lymph nodes; surgical margins; human epidermal growth factor receptor-2 HER-2 expression and tumor regression grade (TRG).

Tumor regression grades were defined as follows: grade 0 (complete remission) is no cancer cells. Grade 1 (partial remission) is single cells or small groups of cancer cells. Grade 2 (low efficacy) is residual cancer outgrown by fibrosis. Grade 3 (poor efficacy) is minimal or no treatment effect and extensive residual cancer cells.

**Statistical Analysis**

Statistical analysis was performed using SPSS version 19.0 software. Quantitative data comparisons were made using the χ² test. Qualitative data were expressed as the mean ± SD and compared using the t test. A P value <0.05 was considered statistically significant.

**RESULTS**

**Clinical Efficacy**

RECIST1.1 evaluation of the concurrent chemoradiotherapy group evaluation showed CR in 0 patients, PR in 20 patients, SD in 16 patients and progressive disease in 0 patients. RR in the concurrent chemoradiotherapy group was 55.6% (20/36). The tumor control rate was 100%. A clinical stage reduction was noted in 61.1% (22/36) of patients.

**Safety Evaluation**

**Toxic Effects of Concurrent Chemoradiotherapy**

Concurrent chemoradiotherapy toxic effects were evaluated using the National Cancer Institute Common Toxicity Criteria (NCI-CTC) version 4.0. Nonhematologic toxic effects included nausea, vomiting, loss of appetite, abnormal liver function, neurological toxicity and radiation dermatitis. Hematologic toxic effects included leukopenia, neutropenia, anemia and thrombocytopenia. These toxic effects were graded 1 to 2 primarily and resolved after symptomatic therapy. There were no chemotherapy-related deaths (Table 2). Treatment was temporarily discontinued for 6 patients due to grade 3 toxic effects and restarted after the toxic effects had lessened or resolved. Chemotherapeutic dosages was reduced for 4 patients.

**Perioperative Complications**

One patient in a concurrent chemoradiotherapy group developed a lymphatic fistula which resolved after 5 days of conservative therapy. One developed moderate pleural effusion and ascites. These symptoms were significantly improved after
TABLE 2. Toxic effects of concurrent chemoradiotherapy in 36 patients, n (%)

| Toxic effects                  | Grade 1   | Grade 2   | Grade 3   | Grade 4   | Grand total |
|--------------------------------|-----------|-----------|-----------|-----------|-------------|
| Hematologic                    |           |           |           |           |             |
| Leukopenia                     | 16 (44.4) | 6 (16.7)  | 2 (5.6)   | 0         | 24 (66.7)   |
| Neutropenia                    | 8 (22.2)  | 6 (16.7)  | 0         | 0         | 14 (38.9)   |
| Anemia                         | 4 (11.1)  | 2 (5.6)   | 0         | 0         | 6 (16.7)    |
| Thrombocytopenia               | 2 (5.6)   | 4 (11.1)  | 4 (11.1)  | 0         | 10 (27.8)   |
| Abnormal liver function        | 6 (16.7)  | 0         | 0         | 0         | 6 (16.7)    |
| Nonhematologic                 |           |           |           |           |             |
| Nausea                         | 4 (11.1)  | 8 (22.2)  | 0         | 0         | 12 (33.3)   |
| Vomiting                       | 8 (22.2)  | 2 (5.6)   | 0         | 0         | 10 (27.8)   |
| Loss of appetite               | 8 (22.2)  | 8 (22.2)  | 0         | 0         | 16 (44.4)   |
| Neurological toxicity          | 2 (5.6)   | 0         | 0         | 0         | 2 (5.6)     |
| Radiation dermatitis           | 2 (5.6)   | 0         | 0         | 0         | 2 (5.6)     |

13 days of conservative therapy. One surgery group patient developed an esophageal jejunal anastomotic fistula that resolved after 52 days of conservative therapy. One patient had a wound dehiscence, which resolved after symptomatic therapy. In the concurrent chemoradiotherapy group, a jejunal tube was indwelt for a month after surgery to ensure early and smooth enteral nutrition.

Surgery

In the neoadjuvant chemoradiotherapy group, surgery was performed after concurrent chemoradiotherapy. The median interval between concurrent chemoradiotherapy and surgery was 6.7 weeks (range: 5.7–8 weeks). Peritoneal cytology results were negative for both groups. The concurrent chemoradiotherapy group consisted of 36 participants who had the following interventions performed at the rates and number of participants indicated: proximal subtotal gastrectomy and jejunal interposition surgery 44.4% (16/36); proximal subtotal gastrectomy and an esophageal gastric remnant anastomosis was performed in 11.1% (4/36); total gastrectomy and Roux-en-Y anastomosis 33.3% (12/36); total gastrectomy and jejunal interposition surgery 11.1% (4/36). The surgery group consisted of 40 patients. The following interventions were performed at the rates and number of participants noted: proximal subtotal gastrectomy and jejunal interposition surgery 45% (18/40); proximal subtotal gastrectomy and esophageal gastric remnant anastomosis 15% (6/40); total gastrectomy and Roux-en-Y anastomosis 40% (16/40).

Pathological Evaluation

R0 resection rates in the concurrent chemoradiotherapy group and the surgery group were 100% and 80% (32/40), respectively. This difference is statistically significant ($\chi^2 = 4.024$, $P = 0.045$). In the concurrent chemoradiotherapy group, the pathological complete RR was 16.7% (6/36), and the total pathological RR (grade 1 + grade 0) was 72.2% (26/36), which was statistically significant ($P < 0.05$). The number of resect lymph nodes in the concurrent chemoradiotherapy group and the surgery group was 26.9 ± 8.4 and 29.4 ± 9.2, respectively. This difference was not statistically significant ($t = 1.725$, $P > 0.05$). Lymph node metastasis occurred in 2.5% (24/968) of the concurrent chemoradiotherapy group and in 7.1% (84/1176) of the surgery group. This difference is statistically significant ($\chi^2 = 12.070$, $P = 0.001$).

DISCUSSION

Sievert has 3 classifications of gastroesophageal junction adenocarcinomas.10,11 The surgery recommended as treatment varies with each. Patient with Sievert II and III adenocarcinomas are less likely to have upper and middle mediastinal lymph node metastasis making surgery using the transabdominal approach by the diaphragmatic hiatus feasible. In neoadjuvant therapy, preoperative concurrent chemoradiotherapy efficacy in treating Sievert II and III gastric cancers has been previously confirmed in clinical trials conducted in Western countries. However, the necessity for neoadjuvant therapy has not been confirmed.12–14 Patients with adenocarcinoma of the gastroesophageal junction were not separated from those with esophageal, or gastric, cancer in most of these studies. The authors were able to identify on a few studies that seem to have been conducted investigating adenocarcinoma at the gastroesophageal junction. This lack of clinical data might result in inappropriate use of combined chemotherapy drugs or radiotherapy dose.

The MAGIC trial, which compared the therapeutic efficacy of cisplatin-based neoadjuvant chemotherapy and surgery alone, resulted in encouraging findings regarding the utility of neoadjuvant therapy.15 That study showed a 5-year survival rate for patients receiving neoadjuvant chemotherapy increased by 13% compared with a surgery group (36% versus 23%). Patients with type II and III adenocarcinoma of the esophagogastric junction accounted for only 11.5% (58/503) of the total subjects studied, but the findings relating to using neoadjuvant therapy to treat esophagogastric junction adenocarcinomas were encouraging.16,17 As a result, focal radiotherapy was added to systemic chemotherapy with the goal of improving therapeutic efficacy. An RR of 55.6%, total tumor control rate of 100% and clinical stage reduction rate of 61.1% suggest that the therapeutic efficacy of concurrent chemoradiotherapy was superior to surgery alone.18,19 These findings were consistent with those of De Paoli et al as an interim analysis of a phase II multicenter study presented at a European Society for Medical Oncology conference.20

The timely implementation of radical resection of the cancer is a key step toward a favorable therapeutic result. Radiotherapy may lessen the focal inflammatory edema and fibrous adhesion of the tumor after chemotherapy. Surgery was performed 6 weeks after chemoradiotherapy.

Among the surgical modalities available for resecting esophagogastric junction adenocarcinoma, proximal subtotal gastrectomy seems to have achieved the best radical resection of the cancer. Preoperative evaluation usually shows that the cancer to be localized at the esophagogastric junction. The choice of surgical modality should be made according to intraoperative exploration findings.21,22 For example, if there is extensive lymph node enlargement at the lesser curvature of the stomach and the

Copyright © by the Southern Society for Clinical Investigation. Unauthorized reproduction of this article is prohibited.
lower borderline of the cancer is blurred, active total gastrectomy is the preferred method for achieving radical resection of the tumor. This is also an important factor in the favorable R0 resection rate for patients receiving concurrent chemoradiotherapy. All the patients in this study that received concurrent chemoradiotherapy also underwent surgical intervention and achieved an R0 resection. No other previous studies have found such results.6,14,23,24 In addition, the pathological complete remission rate in this study was 16.7% and is consistent with previously reported results that ranged from 15% to 30%.25–28

Some investigators have questioned the efficacy of concurrent chemoradiotherapy preceding surgery of adenocarcinomas of the esophagogastric junction and have also expressed concerns about the toxic effects of such therapy. In the CROSS study,29 1 patient receiving chemotherapy, with carboplatin plus paclitaxel and concurrent radiotherapy at 41.4 Gy, developed grade 4 hematologic toxicity and neutropenic fever.30 One other patient died of possible esophageal perforation, heavy bleeding or thrombocytopenia after chemoradiotherapy and before surgery. A Duke University Medical Center study examined the therapeutic efficacy of chemotherapy with fluorouracil in combination with platinum or taxane, and concurrent radiotherapy at 45 Gy, in the treatment of 48 patients with gastric adenocarcinoma or adenocarcinoma of the esophagogastric junction.31 In that study, therapy was discontinued in 6 patients, 2 patients failed to complete the concurrent chemoradiotherapy and 1 patient developed gastric perforation and febrile neutropenia. In this study, 6 patients developed grade 3 hematologic toxicity. Two had leukopenia and 4 had thrombocytopenia. Fever and heavy bleeding were not observed. Chemoradiotherapy-related death was absent. During the perioperative period for patients in this study, 1 patient developed a lymphatic fistula that may have been attributable to an accidental lymphatic injury during the surgery. A single patient developed moderate plural effusion and ascites that might be attributable to abnormal liver function before surgery and also to postoperative stress. These symptoms were resolved after active therapy. Patients in the concurrent chemoradiotherapy group each had an indwelling jejunal feeding tube for 1 month to assure adequate enteral nutrition, and postoperative complications were reduced. The results of this study can be compared with those of the INT-0116 study in which postsurgical adjunctive concurrent chemoradiotherapy was performed.32 In the INT-0116 study, 64% of patients completed the therapy. Three patients experienced chemoradiotherapy-related death. Forty-one percent developed grade 3 toxic effects and 32% had grade 4 toxic effects. This comparison suggests that preoperative concurrent chemoradiotherapy is relatively safe. The findings of this study suggest that the toxic effects of chemoradiotherapy are tolerable. A XELOX regimen is administered in combination with radiotherapy at 45 Gy (25 sessions) that may contribute to the absence of highly toxic taxanes in the chemotherapeutic regimen.

It should be noted that the long-term survival of patients included in this study is unknown. On the basis of available findings, chemotherapy with the XELOX regimen administered in combination with radiotherapy at 45 Gy (25 sessions) seems to be a mildly toxic, but highly effective, therapeutic modality for patients with adenocarcinoma at the gastroesophageal junction. However, additional studies conducted with larger sample sizes and careful patient monitoring would be required to confirm these findings. The results of such studies could be used to significantly improve therapeutic efficacy in treatment of adenocarcinoma of the esophagogastric junction.

REFERENCES

1. Shiibara K, Muro K. Chemoradiotherapy for treatment of esophageal cancer in Japan: current status and perspectives. Gastrointest Cancer Res 2009;3:66–72.
2. Villaflor VM, Allaix ME, Minsky B, et al. Multidisciplinary approach for patients with esophageal cancer. World J Gastroenterol 2012;18:6737–46.
3. Sebag-Montefiore D, Stephens RJ, Steele R, et al. Preoperative radiotherapy versus selective postoperative chemoradiotherapy in patients with rectal cancer (MRC CR07 and NCIC-CTG C016): a multicentre, randomised trial. Lancet 2009;373:811–20.
4. Buergy D, Lohr F, Baack T, et al. Radiotherapy for tumors of the stomach and gastroesophageal junction—a review of its role in multimodal therapy. Radiat Oncol 2012;7:192.
5. Wu AW, Ji JF. Neoadjuvant chemotherapy for locally advanced gastric cancer: with or without radiation. World J Gastrointest Surg 2012;4:27–31.
6. van Hagen P, Hulshof MC, van Lanschot JJ, et al. Preoperative chemoradiotherapy for esophageal or junctional cancer. N Engl J Med 2012;366:2074–84.
7. Pera M, Gallego R, Montagut C, et al. Phase II trial of preoperative chemoradiotherapy with oxaliplatin, cisplatin, and 5-FU in locally advanced esophageal and gastric cancer. Ann Oncol 2012;23:664–70.
8. Rice TW, Rusch VW, Ishwara N, et al. Cancer of the esophagus and esophagogastric junction: data-driven staging for the seventh edition of the American Joint Committee on Cancer/International Union Against Cancer Staging Manuals. Cancer 2010;116:3763–73.
9. Buss MF, Vaughan TL. Epidemiology and risk factors for gastroesophageal junction tumors: understanding the rising incidence of this disease. Semin Radiat Oncol 2013;23:3–9.
10. Brucher BL, Roder JD, Fink U, et al. Prognostic factors in resected primary small bowel tumors. Dig Surg 1998;15:42–51.
11. Feith M, Stein HJ, Siewert JR. Adenocarcinoma of the esophagogastric junction: surgical therapy based on 1602 consecutive resected patients. Surg Oncol Clin N Am 2006;15:751–64.
12. Kurokawa Y, Sasaki M, Doki Y. Treatment approaches to esophagogastric junction tumors. Dig Surg 2013;30:169–73.
13. Lee MS, Mamon HJ, Hong TS, et al. Preoperative cetuximab, irinotecan, cisplatin, and radiation therapy for patients with locally advanced esophageal cancer. Oncologist 2013;18:281–7.
14. Moehler M, Goekel I, Roessler HP, et al. Prospective, open, multi-centre phase II trial to assess safety and efficacy of neoadjuvant radiochemotherapy with docetaxel and oxaliplatin in patients with adenocarcinoma of the oesophagogastric junction. BMC Cancer 2013;13:75.
15. Cunningham D, Allum WH, Stenning SP, et al. Perioperative chemotherapy versus surgery alone for resectable gastroesophageal cancer. N Engl J Med 2006;355:11–20.
16. Cellini F, Morganti AG, Di Matteo FM, et al. Clinical management of gastroesophageal junction tumors: past and recent evidences for the role of radiotherapy in the multidisciplinary approach. Radiat Oncol 2014;9:45.
17. Kleinberg L. Therapy for locally advanced adenocarcinoma of the gastroesophageal junction: optimizing outcome. Semin Radiat Oncol 2013;23:38–50.
18. Ychou M, Boige V, Pignon JP, et al. Perioperative chemotherapy compared with surgery alone for resectable gastroesophageal adenocarcinoma: an FNCLCC and FFCD multicenter phase III trial. J Clin Oncol 2011;29:1715–21.
19. Yoshikawa T, Tanabe K, Nishikawa K, et al. Induction of a pathological complete response by four courses of neoadjuvant chemotherapy for gastric cancer: early results of the randomized phase II COMPASS trial. Ann Surg Oncol 2014;21:213–9.
20. Iester M, Telani S, Brusini P, et al. Central corneal thickness and glaucoma treatment: an Italian multicenter cross-sectional study. J Ocul Pharmacol Ther 2013;29:469–73.

21. Sjoquist KM, Burmeister BH, Smithers BM, et al. Survival after neoadjuvant chemotherapy or chemoradiotherapy for resectable esophageal carcinoma: an updated meta-analysis. Lancet Oncol 2011;12:681–92.

22. Ronellenfitsch U, Schwarzbach M, Hofheinz R, et al. Preoperative chemo(radio)therapy versus primary surgery for gastroesophageal adenocarcinoma: systematic review with meta-analysis combining individual patient and aggregate data. Eur J Cancer 2013;49:3149–58.

23. Koizumi W, Takiuchi H, Yamada Y, et al. Phase II study of oxaliplatin plus S-1 as first-line treatment for advanced gastric cancer (G-SOX study). Ann Oncol 2010;21:1001–5.

24. Tepper J, Krasna MJ, Niedzwiecki D, et al. Phase III trial of trimodality therapy with cisplatin, fluorouracil, radiotherapy, and surgery compared with surgery alone for esophageal cancer: CALGB 9781. J Clin Oncol 2008;26:1086–92.

25. Pepek JM, Chino JP, Willett CG, et al. Preoperative chemoradiotherapy for locally advanced gastric cancer. Radiat Oncol 2013;8:6.

26. Ajani JA, Mansfield PF, Crane CH, et al. Paclitaxel-based chemoradiotherapy in localized gastric carcinoma: degree of pathologic response and not clinical parameters dictated patient outcome. J Clin Oncol 2005;23:1237–44.

27. Ajani JA, Mansfield PF, Janjan N, et al. Multi-institutional trial of preoperative chemoradiotherapy in patients with potentially resectable gastric carcinoma. J Clin Oncol 2004;22:2774–80.

28. Rohatgi PR, Mansfield PF, Crane CH, et al. Surgical pathology stage by American Joint Commission on Cancer criteria predicts patient survival after preoperative chemoradiation for localized gastric carcinoma. Cancer 2006;107:1475–82.

29. An JY, Kim HJ, Cheong JH, et al. Pathologic and oncologic outcomes in locally advanced gastric cancer with neoadjuvant chemotherapy or chemoradiotherapy. Yonsei Med J 2013;54:888–94.

30. Wong AS, Soo RA, Lu JJ, et al. Paclitaxel, 5-fluorouracil and hydroxyurea concurrent with radiation in locally advanced nasopharyngeal carcinoma. Ann Oncol 2006;17:1152–7.

31. Jones LW, Fels DR, West M, et al. Modulation of circulating angiogenic factors and tumor biology by aerobic training in breast cancer patients receiving neoadjuvant chemotherapy. Cancer Prev Res (Phila) 2013;6:925–37.

32. MacDonald JS, Smalley SR, Benedetti J, et al. Chemoradiotherapy after surgery compared with surgery alone for adenocarcinoma of the stomach or gastroesophageal junction. N Engl J Med 2001;345:725–30.